If Danes were given to superstition they would be waving every lucky charm going in the direction of Lars Fruergaard Jorgensen. More, they should be giving him daily thanks and checking on his health.
For Jorgensen, 56, has transformed their entire economy. It sounds bizarre, that one individual can account for so much – Denmark is a country after all of six million people with a land mass of 16,580 square miles, making it 130th in the world by size. Its capital, Copenhagen is one of the biggest cities in Europe.
One guy, come on. But it’s true. The balding, bespectacled, soberly dressed Jorgensen is chief executive of Novo Nordisk, the laboratory that has seen its two flagship products, Ozempic used to treat diabetes, and Wegovy, anti-obesity, take the world by storm. As a result, his company’s market capitalisation of 2.9 billion kroner (over €400bn) has outgrown Denmark’s GDP of 2.8 billion kroner.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies